Immunotherapy May Move Into Advanced Gynecologic Cancers

The immunotherapy agent Opdivo (nivolumab) showed clinical acitivty in women who had recurrent/metastatic cervical cancer, and was active to a lesser extent in vaginal and vulvar cancers, according to results from the CheckMate-358 trial.
BY Jason Harris
PUBLISHED July 20, 2017
The immunotherapy agent Opdivo (nivolumab) showed clinical acitivty in women who had recurrent/metastatic cervical cancer, and was active to a lesser extent in vaginal and vulvar cancers, according to results from the CheckMate-358 trial.

Antoine Hollebecque, M.D., with Institut de Cancérologie Gustave Roussy in Villejuif, France, presented the results at the 2017 ASCO Annual Meeting. He said the overall response rate (ORR) across the three tumor types was was 20.8 percent and the disease control rate (DCR) was 70.8 percent. Median follow-up was 31 weeks.

“Nivolumab demonstrated encouraging clinical activity in patients with recurrent or metastatic cervical, vagina, and vulvar cancers,” Hollegecque said. “These data support further evaluation of nivolumab in these patients, including in combination with other therapies.”

Three-month progression-free survival (PFS) was 73.9 percent. Median PFS was 5.5 months. Six-month overall survival (OS) was 87.1 percent. Median OS was not reached.

Hollegecque said that as much as 69 percent of vulvar cancers, 75 percent of vaginal cancers, and more than 90 percent of cervical cancers can be attributed to HPV. In the recurrent/metastatic setting, ORR is 0 percent to 14 percent for these cancers.

“HPV can evade host immune surveillance through increased expression of PD-L1, enabling viral persistence and the development of malignant lesions,” he said. “Nivolumab, a PD-1 inhibitor, has demonstrated antitumor activity in several tumor types and the role of immunotherapy is evolving in gynecological malignancies.”

Researchers enrolled 24 patients into the gynecologic arm of the CheckMate-358 trial from October 2015 to February 2016. Nineteen patients (79.2 percent) had cervical cancer and 5 (20.8 percent) had vaginal or vulvar cancer. Eligible patients had an ECOG performance score of 0 to 1 and fewer than two prior systemic therapies for relapsed/metastatic disease.

Fourteen patients (58.3 percent) were positive for HPV. HPV status was unknown for the 10 remaining patients (41.7 percent).

All patients were treated with 240 mg of Opdivo every two weeks until progression or unacceptable toxicity.

While the overall DCR was 70.8 percent, Opdivo induced stronger responses in women with cervical cancer.

At the July 2016 data cutoff, there was one complete response (CR) and four partial responses (PR), all among patients with cervical cancer. The best response among patients with vulvar or vaginal cancer was stable disease (80 percent).

Duration of response was not reached in any group, but Hollegecque said all objective responses lasted at least six months.

“At the data cutoff, the five patients with an objective response were still ongoing,” he said. “Nine out of 24 patients were still free from progression.”

ORR was 28.6 percent for patients who received Opdivo in first-line (seven patients) and 17.6 percent among those who received at least 1 previous systemic treatment (17 patients). DCR was 71.4 percent and 70.6 percent, respectively.

PD-L1 expression was at least 1 percent in 10 patients (41.7 percent) and less than 1 percent in three patients (12.5 percent). Ten patients were not tested for PD-L1 expression and one patient was not evaluable.

ORR was 20 percent among patients in the PD-L1 expressing group with one CR, one PR and six patients with stable disease, for a DCR of 80 percent. ORR was 33.3 percent in the nonexpressing group. One patient each had PR and stable disease, for a DCR of 66.7 percent.

Among HPV-positive patients, there were 4 PRs (28.6 percent) and four patients with stable disease. ORR was 28.6 percent and DCR was 57.1 percent. Among patients with unknown HPV-status, there was one CR and 8 patients with stable disease. ORR was 10 percent and DCR was 90 percent.

Seventeen patients (70.8 percent) experienced a treatment-related adverse event (AE) and 3 (12.5 percent) experienced a grade 3/4 treatment-related AE, including diarrhea, hyponatremia, syncope, and hepatocellular injury. There were no treatment-related deaths.

“The observed safety profile was manageable and consistent with previous results seen with nivolumab monotherapy,” Hollegecque said.
Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In